CochLear Revenue 2023-2024 | CHEOY
CochLear annual/quarterly revenue history and growth rate from 2023 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- CochLear revenue for the quarter ending June 30, 2024 was $0M, a 0% increase year-over-year.
- CochLear revenue for the twelve months ending June 30, 2024 was $0M, a 0% increase year-over-year.
- CochLear annual revenue for 2024 was $1.466B, a 12.48% increase from 2023.
- CochLear annual revenue for 2023 was $1.303B, a 8.99% increase from 2022.
- CochLear annual revenue for 2022 was $1.196B, a 3.73% increase from 2021.
| CochLear Annual Revenue (Millions of US $) |
|
|---|---|
| 2024 | $1,466 |
| 2023 | $1,303 |
| 2022 | $1,196 |
| 2021 | $1,153 |
| 2020 | $887 |
| 2019 | $1,020 |
| 2018 | $1,057 |
| 2017 | $945 |
| 2016 | $824 |
| CochLear Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2024-06-30 | |
| 2023-12-31 | |
| 2023-06-30 | |
| 2022-06-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $11.380B | $1.488B |
| Cochlear Limited provides implantable hearing solutions principally in the Americas, Europe, the Middle East, Africa and the Asia Pacific. The company offers cochlear implants, including Nucleus 7 and Kanso sound processors; Carina middle-ear implants and accessories and Baha bone conduction implants. Cochlear Limited is based in Sydney, Australia. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $142.368B | 26.70 |
| Elevance Health (ELV) | United States | $93.458B | 12.06 |
| CVS Health (CVS) | United States | $81.990B | 12.00 |
| Cencora (COR) | United States | $56.269B | 20.42 |
| Natera (NTRA) | United States | $20.939B | 0.00 |
| DiDi Global (DIDIY) | China | $20.365B | 29.93 |
| BioMerieux (BMXMF) | France | $15.507B | 0.00 |
| ICON (ICLR) | Ireland | $12.058B | 10.95 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $11.881B | 0.00 |
| Solventum (SOLV) | United States | $11.461B | 10.69 |
| Revvity (RVTY) | United States | $11.373B | 19.20 |
| Doximity (DOCS) | United States | $10.781B | 56.07 |
| Viatris (VTRS) | United States | $9.955B | 3.15 |
| Medpace Holdings (MEDP) | United States | $8.805B | 23.39 |
| Avantor (AVTR) | United States | $8.647B | 12.56 |
| Sonic Healthcare (SKHHY) | Australia | $8.152B | 0.00 |
| HealthEquity (HQY) | United States | $7.475B | 36.77 |
| Charles River Laboratories (CRL) | United States | $5.761B | 11.36 |
| Bausch + Lomb (BLCO) | Canada | $4.848B | 22.13 |
| Amplifon S.p.A (AMFPF) | Italy | $4.285B | 22.62 |
| Alignment Healthcare (ALHC) | United States | $3.446B | 0.00 |
| Organon (OGN) | United States | $3.421B | 3.45 |
| GeneDx Holdings (WGS) | United States | $3.283B | 389.90 |
| Sotera Health (SHC) | United States | $3.210B | 18.54 |
| BrightSpring Health Services (BTSG) | United States | $3.069B | 31.87 |
| Surgery Partners (SGRY) | United States | $2.863B | 32.84 |
| Concentras Parent (CON) | United States | $2.815B | 14.64 |
| Progyny (PGNY) | United States | $1.967B | 43.32 |
| Premier (PINC) | United States | $1.862B | 11.92 |
| Ardent Health Partners (ARDT) | United States | $1.806B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.788B | 38.83 |
| Agilon Health (AGL) | United States | $1.569B | 0.00 |
| PACS (PACS) | United States | $1.486B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.285B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.078B | 9.04 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.039B | 0.00 |
| CareDx (CDNA) | United States | $1.008B | 17.10 |
| Establishment Labs Holdings (ESTA) | $0.873B | 0.00 | |
| AMN Healthcare Services Inc (AMN) | United States | $0.770B | 6.09 |
| Embecta (EMBC) | United States | $0.730B | 5.00 |
| Nutex Health (NUTX) | United States | $0.579B | 11.35 |
| QDM (QDMI) | Hong Kong, SAR China | $0.554B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.530B | 14.04 |
| Sonida Senior Living (SNDA) | United States | $0.444B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.412B | 0.00 |
| Enhabit (EHAB) | United States | $0.402B | 37.90 |
| LifeMD (LFMD) | United States | $0.384B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.349B | 0.00 |
| SBC Medicals (SBC) | United States | $0.347B | 0.00 |
| DocGo (DCGO) | United States | $0.233B | 9.50 |
| Oncology Institute (TOI) | United States | $0.189B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.184B | 0.00 |
| Beauty Health (SKIN) | United States | $0.125B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.112B | 0.00 |
| OncoCyte (OCX) | United States | $0.089B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.084B | 0.00 |
| So-Young (SY) | China | $0.084B | 0.00 |
| Biodesix (BDSX) | United States | $0.078B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.077B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.070B | 0.00 |
| NeueHealth (NEUE) | United States | $0.057B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.029B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.021B | 0.00 |
| ModivCare (MODV) | United States | $0.018B | 6.32 |
| SeaStar Medical Holding (ICU) | United States | $0.012B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.012B | 0.00 |
| KindlyMD (KDLY) | United States | $0.011B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.004B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |